Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — Q1 2026 Earnings Presentation
20 slides from Crinetics Pharmaceuticals's earnings presentation, May 7, 2026
Slide 1: First Quarter 2026 Financial Results and Business Update
May 7, 2026 First Quarter 2026 Financial Results and Business Update
Slide 2: Forward Looking Statements and Non-GAAP Measures
Forward Looking Statements and Non-GAAP Measures This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are for
Slide 3: Introductory Remarks
Introductory Remarks Click icon to add picture Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 3
Slide 4: Crinetics is an Endocrinology Powerhouse
$10.3M in Palsonify™ net product revenue in 1Q2026 Compelling trajectory with continued strong execution on launch and clinical development World-class R&D capabilities and capital efficient Crinetics is an development with early-stage proof of concept Endocrinology Deep clinical stage pipeline with
Slide 5: Commercial Update
Commercial Update Click icon to add picture Isabel Kalofonos Chief Commercial Officer CRINETICS PHARMACEUTICALS | 5
Slide 6: Driving Expansion on the Palsonify Launch
Driving Expansion on the Palsonify Launch Strong demand across all patient segments $10.3M Expanding breadth and depth 1Q2026 Net Product Revenue Solid reimbursement coverage D, living with acromegaly Note: Data as of March 31, 2026. CRINETICS PHARMACEUTICALS | 6
Slide 7: Robust Launch Metrics Reflect Strong Execution
Robust Launch Metrics Reflect Strong Execution Strong Demand from All Expanding Breadth and Solid Reimbursement Patient Segments Depth of Prescribers Coverage 232 ~70% Enrollment Forms in Q1 263 Patients on Therapy Reimbursed Cumulative Unique at End of Q1 Share of Cumulative Enrollments Palsonify P
Slide 8: Harnessing the Power of Patient Experience to Build Awareness and Advocacy for Palsonify
Harnessing the Power of Patient Experience to Build Awareness and Advocacy for Palsonify Patient Ambassador Program features compelling stories from real Palsonify patients ü Facilitates peer-to-peer engagement ü Empowers patients with knowledge to advocate for their own care CrinetiCARE® continues
Slide 9: Robust Launch Metrics Reflect Strong Execution
Robust Launch Metrics Reflect Strong Execution Strong Demand from All Expanding Breadth and Solid Reimbursement Patient Segments Depth of Prescribers Coverage 232 ~70% Enrollment Forms in Q1 263 Patients on Therapy Reimbursed Cumulative Unique at End of Q1 Share of Cumulative Enrollments Palsonify P
Slide 10: Palsonify Efficacy is Differentiated
Palsonify Efficacy is Differentiated Data from Published Indirect Treatment Comparison Palsonify Subcu Octreotide Oral Octreotide Recently Published Indirect Treatment Comparison Highlights Efficacy of Palsonify Relative to Other New Therapies Salvatori R et al. J Clin Endocrinol Metab. 2026; doi:10
Slide 11: Improved Payer Coverage Based on Strength of Data and Value Proposition
Improved Payer Coverage Based on Strength of Data and Value Proposition Ø On Track to Achieve 75% of Covered Lives by 3Q2026 Unprecedented Safety and Efficacy Maintain Control Ability to achieve rapid biochemical Limit patient and societal and symptom control based on burden of uncontrolled Phase 3
Slide 12: Pipeline Updates
Pipeline Updates Alan Krasner Chief Endocrinologist CRINETICS PHARMACEUTICALS | 12
Slide 13: What's Next: Pipeline of Transformative Clinical Assets
What’s Next: Pipeline of Transformative Clinical Assets PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL APPROVED US Patients CANDIDATE Acromegaly (US) Paltusotine 36,0001 (Oral SST2 Agonist) Acromegaly (EU) Paltusotine Carcinoid Syndrome 18,000-34,000² (Oral SST2 Agonist) Atume
Slide 14: Raising Awareness of Palsonify and Differentiated Pipeline at Key Medical Congresses
Raising Awareness of Palsonify and Differentiated Pipeline at Key Medical Congresses April 22–24, 2026 JUNE 13-16, 2026 • Presentations across differentiated portfolio, including • Long-term efficacy / safety of Palsonify in acromegaly • Full Phase 2 data for atumelnant in CAH • Additional patients
Slide 15: Financial Update
Financial Update Click icon to add picture Toby Schilke Chief Financial Officer CRINETICS PHARMACEUTICALS | 15
Slide 16: Financial Results (unaudited)
Financial Results (unaudited) Three Months Ended (in millions) March 31, 2026 December 31, 2025 Product Revenue, Net $ 10.3 $ 5.4 Collaboration and License 0.4 0.7 Revenue Revenues $ 10.7 $ 6.2 Cost of Product Revenue (0.2) (1.1) R&D Expenses (100.1) (85.1) SG&A Expenses (50.8) (53.7) Loss from Oper
Slide 17: $1.3 Billion Cash Balance Funds Current Operating Plan and Strategic Initiatives
$1.3 Billion Cash Balance Funds Current Operating Plan and Strategic Initiatives Into 2030 Disciplined execution on multiple Cash runway based on current operating plan value-creating milestones including: Ø Commercialization of PALSONIFY $600 Million - $650 Million Ø Pivotal readouts for ongoing cl
Slide 18: Closing Remarks
Closing Remarks Click icon to add picture Scott Struthers Founder & Chief Executive Officer CRINETICS PHARMACEUTICALS | 18
Slide 19: Upcoming Milestones
Upcoming Upcoming Milestones Milestones Potential 2026 Milestone Commercial execution of PALSONIFY in the U.S. Paltusotine Advancing paltusotine in other geographies Phase 3 CAREFNDR readout in carcinoid syndrome Longer duration data from OLE portion of TouCAHn in adult CAH Phase 3 CALM data in adul
Slide 20: Thank You
rinetics ee 8 8 rr
Crinetics Pharmaceuticals — Q1 2026 Earnings Presentation on 6ix